High-risk gaps in the manufacturing process of cell and gene therapies are often under-estimated by organizations, resulting in major setbacks in the transition from a clinical-stage to a commercial therapy. Learn how Lonza’s highly tailored, step-by-step approach to commercial readiness can help you ensure a robust, reproducible and commercially viable Good Manufacturing Practice (GMP) process, de-risking your path to successful commercialization.
Watch Video